Daniel Joseph O Connell Acumen Pharmaceuticals, Inc. (ABOS) insider trading activity

Daniel Joseph O Connell is Chief Executive Officer of Acumen Pharmaceuticals, Inc.. Currently has a direct ownership of 881,275 shares of ABOS, which is worth approximately $1.57 Million. The most recent transaction as insider was on Jan 22, 2026, when has been sold 2,689 shares (Common Stock) at a price of $1.88 per share, resulting in proceeds of $5,055. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 881K

32.03% 3M change

32.03% 12M change

Total Value Held $1.57 Million

Daniel Joseph OConnell Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 22 2026	SELL Open market or private sale	$5,055 $1.88 p/Share	2,689 Reduced 0.3%	881,275 Common Stock
Jan 21 2026	SELL Open market or private sale	$16,916 $1.81 p/Share	9,346 Reduced 1.05%	883,964 Common Stock
Jan 20 2026	BUY Grant, award, or other acquisition	-	299,800 Added 25.13%	893,310 Common Stock
Jan 12 2026	SELL Open market or private sale	$9,321 $1.73 p/Share	5,388 Reduced 0.9%	593,510 Common Stock
Jan 09 2026	SELL Open market or private sale	$22,776 $1.76 p/Share	12,941 Reduced 2.12%	598,898 Common Stock
Jan 08 2026	SELL Open market or private sale	$14,820 $1.82 p/Share	8,143 Reduced 1.31%	611,839 Common Stock
Jan 07 2026	SELL Open market or private sale	$75,132 $1.99 p/Share	37,755 Reduced 5.74%	619,982 Common Stock

Jan 06 2026	SELL Open market or private sale	$10,050 $1.97 p/Share	5,102 Reduced 0.77%	657,737 Common Stock
Jan 05 2026	SELL Open market or private sale	$9,158 $1.97 p/Share	4,649 Reduced 0.7%	662,839 Common Stock
Jan 21 2025	SELL Open market or private sale	$20,064 $1.59 p/Share	12,619 Reduced 1.86%	667,488 Common Stock
Jan 07 2025	BUY Grant, award, or other acquisition	-	225,400 Added 24.89%	680,107 Common Stock
Jan 03 2025	SELL Open market or private sale	$87,911 $1.84 p/Share	47,778 Reduced 9.51%	454,707 Common Stock
Jan 19 2024	SELL Open market or private sale	$52,744 $3.47 p/Share	15,200 Reduced 2.94%	502,485 Common Stock
Jan 02 2024	BUY Grant, award, or other acquisition	-	401,000 Added 43.65%	517,685 Common Stock
Jan 17 2023	BUY Grant, award, or other acquisition	-	114,000 Added 49.42%	116,685 Common Stock
Nov 30 2021	BUY Exercise of conversion of derivative security	$4,997 $4.47 p/Share	1,118 Added 29.4%	2,685 Common Stock
Jul 06 2021	SELL Payment of exercise price or tax liability	$160 $16.0 p/Share	10 Reduced 0.63%	1,567 Common Stock
Jul 06 2021	BUY Exercise of in-the-money or at-the-money derivatives securities	$156 $4.47 p/Share	35 Added 2.17%	1,577 Common Stock
Jul 06 2021	BUY Conversion of derivative security	-	123 Added 7.39%	1,542 Common Stock

DJO

Daniel Joseph O Connell

Chief Executive Officer

Charlottesville, VA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells ABOS shares.

Notify only if

Value

Insider Trading

Get notified when an Acumen Pharmaceuticals, Inc. insider buys or sells ABOS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Acumen Pharmaceuticals, Inc.

Track Activities on ABOS

Account